General Information Infectious Disease Cancer Topical Microbicides Immune Modulation and Inflammation April 4th 2008: ImQuest scientists present important HIV Microbicide results at Microbicides 2008 in Delhi, India.     April 1st 2008: ImQuest publishes results of structure activity relationship study with pyrimidinedione HIV inhibitors.     September 24th 2007: ImQuest Life Sciences announces the appointment of Robert Schooley, M.D. to its Scientific Advisory Board.     September 21st 2007: ImQuest Life Sciences announces the appointment of David Ho, M.D. to its Scientific Advisory Board.     September 20th 2007: ImQuest Life Sciences announces the appointment of Richard J. Whitley, M.D. as Chairman of its Scientific Advisory Board.     April 25th 2007: ImQuest Life Sciences Receives Grant from International Partnership for Microbicides to Develop Novel Microbicide     April 25th 2006: ImQuest Life Sciences Licenses Piperazine Series of Anti-Cancer Therapeutic Compounds from Samjin Pharmaceutical Co.     Meet the Management | Directors and Advisors Our Mission ImQuest Life Sciences will develop new, novel, first in class drugs for the treatment of infectious disease, cancer and inflammation. We will fulfill this mission by developing key strategic alliances and partnerships with individuals, academic institutions, biotechnology and pharmaceutical companies which possess key technology requiring the resources of ImQuest Life Sciences to achieve drug development success. ImQuest Life Sciences will become a leader in the development of exciting new drugs for unmet medical needs throughout the world, providing new therapeutic resources for the effective treatment and prevention of human disease.   Our Focus ImQuest Life Sciences is currently focusing on the following drug development programs, through the formation of alliances and partnerships as well as through exclusive world wide licensing: Therapies for the treatment of HIV Topical microbicides for the prevention of transmission of HIV and other sexually transmitted infections Therapies for the treatment of HBV and HCV Therapies for the treatment of cancer   Our Strategy ImQuest Life Sciences will form strategic drug development alliances with individuals, academic institutions, biotechnology companies and pharmaceutical companies which possess novel drug development strategies and technology that will facilitate the development of new drugs for the treatment of infectious disease, cancer and inflammation. Our portfolio development strategy has been facilitated by our alliance with ImQuest BioSciences, an independent provider of critical drug development and consultative services to the pharmaceutical industry, in light of their deep and broad experience with the development of therapeutic agents for human disease. In addition to developing our own proprietary technologies, ImQuest Life Sciences will provide a much needed vehicle for the clients of ImQuest BioSciences to add significant value to their portfolio through the performance of ImQuest-sponsored advanced preclinical pharmacology and toxicology and Phase 1 and 2 human clinical trials. In this way, ImQuest Life Sciences will assist in the provision of the all-important proof of concept studies for novel first in class agents and these studies will be performed by an experienced team of investigators.   Infectious Disease IQP-0410 for  HIV HBV Lead Discovery Anti-Cancer Agents IQP-0303 for leukemia IQP-0304 for prostate cancer Topical Microbicides IQP-0528 IQP-0831 IQP-1187

Copyright © 2006, ImQuest Life Sciences. Site Map | Search | Privacy Policy | Terms & Conditions. Site by Synapse Communications.